Close Menu

NEW YORK (GenomeWeb News) – Evotec and the Jain Foundation today said they have extended and expanded their 2012 research collaboration aimed at dysferlinopathy.

Terms of the expanded deal were not disclosed.

Evotec and Jain started a research project in 2012 to develop a cell-based high-throughput screening assay using dysferlin-deficient cells with the goal of identifying compounds that can improve the well-being of dysferlin-deficient muscle cells.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Hastings Center's Erik Parens argues in a Scientific American opinion piece that the current pandemic underscores the need to reconsider the hope placed in genomic medicine. 

The Los Angeles Times writes that Operation Warp Speed has an ambitious timeline for developing a COVID-19 vaccine.

The Sydney Morning Herald reports that Australia is launching its trial of preconception carrier testing Tuesday.

In PNAS this week: autosomal genes commonly affected by loss-of-function variants, variants implicated in testis development disorders, and more.